Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human randomized placebo-controlled study of MT-4129 in healthy volunteers
NL-OMON43193Phase 1Active, not recruiting
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in hypertension (HTN), heart failure (HF) and Not applicable comparing MT-4129 with Placebo (2 arms). Primary endpoint: Safety and tolerability. Started Nov 2016; status: active, not recruiting.
02
Drugs
lorundrostat
03
Conditions
hypertension (HTN)heart failure (HF)Not applicable
Beyond the preview
Go deeper on NL-OMON43193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43193.